Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer

FEBS Journal

Volumn 279, Issue 15, 2012, Pages 2695-2713

  Kreiling, Jodi L ^a   Montgomery, Michelle A ^b   Wheeler, Joseph R ^b   Kopanic, Jennifer L ^b   Connelly, Christopher M ^b   Zavorka, Megan E ^b   Allison, Jenna L ^b   MacDonald, Richard G ^b  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

dimerization; dominant negative; ectodomain shedding; mannose 6 phosphate receptor; truncation mutants

Indexed keywords

HETERODIMER; MANNOSE 6 PHOSPHATE; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR;

ARTICLE; CELL LYSATE; CELL MEMBRANE; CELL SURFACE; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IGF2R GENE; IMMUNOPRECIPITATION; INTERNALIZATION; LIGAND BINDING; LYSOSOME; M6P GENE; MALIGNANT NEOPLASTIC DISEASE; OLIGOMERIZATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RECEPTOR BINDING; TUMOR SUPPRESSOR GENE; WILD TYPE;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELL MEMBRANE; DIMERIZATION; DNA, COMPLEMENTARY; EXTRACELLULAR SPACE; HALF-LIFE; HEK293 CELLS; HUMANS; LYSOSOMES; MUTAGENESIS; MUTANT PROTEINS; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, IGF TYPE 2; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84863840659     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08652.x     Document Type: Article

References (59)

1. Martin-Kleiner I, &, Gall Troselj K, (2010) Mannose-6-phosphate/ insulin-like growth factor 2 receptor (M6P/IGF2R) in carcinogenesis. Cancer Lett 289, 11-22.
2. Dahms NM, &, Hancock MK, (2002) P-type lectins. Biochim Biophys Acta 1572, 317-340.
3. Dahms NM, (1996) Insulin-like growth factor II/cation-independent mannose 6-phosphate receptor and lysosomal enzyme recognition. Biochem Soc Trans 24, 136-141.
4. El-Shewy HM, &, Luttrell LM, (2009) Insulin-like growth factor-2/mannose-6-phosphate receptors. Vitam Horm 80, 667-697.
5. Brown J, Delaine C, Zaccheo OJ, Siebold C, Gilbert RJ, van Boxel G, Denley A, Wallace JC, Hassan AB, Forbes BE, et al. (2008) Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J 27, 265-276.
6. O'Gorman DB, Costello M, Weiss J, Firth SM, &, Scott CD, (1999) Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells. Cancer Res 59, 5692-5694.
7. O'Gorman DB, Weiss J, Hettiaratchi A, Firth SM, &, Scott CD, (2002) Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 143, 4287-4294.
8. Li J, &, Sahagian GG, (2004) Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor. Oncogene 23, 9359-9368.
9. Leksa V, Godár S, Cebecauer M, Hilgert I, Breuss J, Weidle UH, Horejsí V, Binder BR, &, Stockinger H, (2002) The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration. J Biol Chem 277, 40575-40582.
10. Olson LJ, Dahms NM, &, Kim J-JP, (2004) The N-terminal carbohydrate recognition site of the cation-independent mannose 6-phosphate receptor. J Biol Chem 279, 34000-34009.
11. Olson LJ, Yammani RD, Dahms NM, &, Kim J-JP, (2004) Structure of uPAR, plasminogen, and sugar-binding sites of the 300 kDa mannose 6-phosphate receptor. EMBO J 223, 2019-2028.
12. Brown J, Jones EY, &, Forbes BE, (2009) Keeping IGF-II under control: lessons from the IGF-II-IGF2R crystal structure. Trends Biochem Sci 34, 612-619.
13. Kreiling JL, Byrd JC, &, MacDonald RG, (2005) Domain interactions of the insulin-like growth factor II/mannose 6-phosphate receptor. J Biol Chem 280, 21067-21077.
14. York SJ, Arneson LS, Gregory WT, Dahms NM, &, Kornfeld S, (1999) The rate of internalization of the mannose 6-phosphate/insulin-like growth factor II receptor is enhanced by multivalent ligand binding. J Biol Chem 274, 1164-1171.
15. De Souza AT, Hankins GR, Washington MK, Orton TC, &, Jirtle RL, (1995) M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11, 447-449.
16. Byrd JC, &, MacDonald RG, (2000) Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor. Negative cooperativity and receptor oligomerization. J Biol Chem 275, 18638-18646.
17. Byrd JC, Park JHY, Schaffer BS, Garmroudi F, &, MacDonald RG, (2000) Dimerization of the insulin-like growth factor II/mannose 6-phosphate receptor. J Biol Chem 275, 18647-18656.
18. Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM, Zou T-T, Shi Y-Q, Lei J, Cottrell J, et al. (1996) Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 14, 255-257.
19. Ouyang H, Shiwaku HO, Hagiwara H, Miura K, Abe T, Kato Y, Ohtani H, Shiiba K, Souza RF, Meltzer SJ, et al. (1997) The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res 57, 1851-1854.
20. Kong F-M, Anscher MS, Washington MK, Killian KJ, &, Jirtle RL, (2000) M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19, 1572-1578.
21. Sahagian GG, (1984) The mannose 6-phosphate receptor: function, biosynthesis and translocation. Biol Cell 51, 207-214.
22. MacDonald RG, &, Czech MP, (1985) Biosynthesis and processing of the type II insulin-like growth factor receptor in H-35 hepatoma cells. J Biol Chem 260, 11357-11365.
23. Blok J, Mulder-Stapel AA, Ginsel LA, &, Daems WT, (1981) The effect of chloroquine on lysosomal function and cell-coat glycoprotein transport in the absorptive cells of cultured human small-intestinal tissue. Cell Tissue Res 218, 227-251.
24. 2-adrenergic receptor down-regulation. Evidence for a pathway that does not require endocytosis. J Biol Chem 274, 28900-28908.
25. Kiess W, Greenstein LA, White RM, Lee L, Rechler MM, &, Nissley SP, (1987) Type II insulin-like growth factor receptor is present in rat serum. Proc Natl Acad Sci USA 84, 7720-7724.
26. Causin C, Waheed A, Braulke T, Junghans U, Maly P, Humbel RE, &, von Figura K, (1988) Mannose 6-phosphate/insulin-like growth factor II-binding proteins in human serum and urine. Their relation to the mannose 6-phosphate/insulin-like growth factor II receptor. Biochem J 252, 795-799.
27. MacDonald RG, Tepper MA, Clairmont KB, Perregaux SB, &, Czech MP, (1989) Serum form of the rat insulin-like growth factor II/mannose 6-phosphate receptor is truncated in the carboxyl-terminal domain. J Biol Chem 264, 3256-3261.
28. Clairmont KB, &, Czech MP, (1991) Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J Biol Chem 266, 12131-12134.
29. Black RA, (2002) Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34, 1-5.
30. Mullberg J, Althoff K, Jostock T, &, Rose-John S, (2000) The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 11, 27-38.
31. Tong PY, Gregory W, &, Kornfeld S, (1989) Ligand interactions of the cation-independent mannose 6-phosphate receptor. The stoichiometry of mannose 6-phosphate binding. J Biol Chem 264, 7962-7969.
32. Ghosh P, Dahms NM, &, Kornfeld S, (2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4, 202-213.
33. MacDonald RG, &, Byrd JC, (2003) The insulin-like growth factor II/mannose 6-phosphate receptor: implications for IGF action in breast cancer. Breast Dis 17, 61-72.
34. Pollak MN, Schernhammer ES, &, Hankinson SE, (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4, 505-518.
35. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, &, Jirtle RL, (1995) Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10, 1725-1729.
36. Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, &, Jirtle RL, (1996) M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 12, 2003-2009.
37. Filson AJ, Louvi A, Efstratiadis A, &, Robertson EJ, (1993) Rescue of the T-associated maternal effect in mice carrying null mutations in Igf-2 and Igf2r, two reciprocally imprinted genes. Development 118, 731-736.
38. Ludwig T, Eggenschwiler J, Fisher P, D'Ercole AJ, Davenport ML, &, Efstratiadis A, (1996) Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 177, 517-535.
39. Wise TL, &, Pravtcheva DD, (2006) Delayed onset of Igf2-induced mammary tumors in Igf2r transgenic mice. Cancer Res 66, 1327-1336.
40. Devi GR, De Souza AT, Byrd JC, Jirtle RL, &, MacDonald RG, (1999) Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers. Cancer Res 59, 4314-4319.
41. Byrd JC, Devi GR, De Souza AT, Jirtle RL, &, MacDonald RG, (1999) Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations. J Biol Chem 274, 24408-24416.
42. Schähs P, Weidinger P, Probst OC, Svoboda B, Stadlmann J, Beug H, Waerner T, &, Mach L, (2008) Cellular repressor of E1A-stimulated genes is a bona fide lysosomal protein which undergoes proteolytic maturation during its biosynthesis. Exp Cell Res 314, 3036-3047.
43. Di Bacco A, &, Gill G, (2003) The secreted glycoprotein CREG inhibits cell growth dependent on the mannose-6-phosphate/insulin-like growth factor II receptor. Oncogene 22, 5436-5445.
44. Han Y, Cui J, Tao J, Guo L, Guo P, Sun M, Kang J, Zhang X, Yan C, &, Li S, (2009) CREG inhibits migration of human vascular smooth muscle cells by mediating IGF-II endocytosis. Exp Cell Res 315, 3301-3311.
45. Han Y-L, Guo P, Sun M-Y, Guo L, Luan B, Kang J, Yan C-H, &, Li S-H, (2008) Secreted CREG inhibits cell proliferation mediated by mannose 6-phosphate/insulin-like growth factor II receptor in NIH3T3 fibroblasts. Genes Cells 13, 977-986.
46. Han Y-L, Luan B, Sun M, Guo L, Guo P, Tao J, Deng J, Wu G, Liu S, Yan C, et al. (2011) Glycosylation-independent binding to extracellular domains 11-13 of mannose-6-phosphate/insulin-like growth factor-2 receptor mediates the effects of soluble CREG on the phenotypic modulation of vascular smooth muscle cells. J Mol Cell Cardiol 50, 723-730.
47. Seals DF, &, Courtneidge SA, (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17, 7-30.
48. Arribas J, &, Massague J, (1995) Transforming growth factor-α and β-amyloid precursor protein share a secretory mechanism. J Cell Biol 128, 433-441.
49. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, et al. (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102, 1186-1195.
50. Duffy MJ, McKiernan E, O'Donovan N, &, McGowan PM, (2009) Role of ADAMs in cancer formation and progression. Clin Cancer Res 15, 1140-1144.
51. Edwards DR, Handsley MM, &, Pennington CJ, (2008) The ADAM metalloproteinases. Mol Aspects Med 29, 258-289.
52. Leksa V, Loewe R, Binder B, Schiller HB, Eckerstorfer P, Forster F, Cardona AS, Ondrovicova G, Kutejova E, Steinhuber E, et al. (2011) Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation. Circ Res 108, 676-685.
53. Andersson S, Davis DL, Dahlbäck H, Jörnvall H, &, Russell DW, (1989) Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem 264, 8222-8229.
54. Oshima A, Nolan CM, Kyle JW, Grubb JH, &, Sly WS, (1988) The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells. J Biol Chem 263, 2553-2562.
55. Garmroudi F, Devi G, Slentz DH, Schaffer BS, &, MacDonald RG, (1996) Truncated forms of the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor encompassing the IGF-II binding site: characterization of a point mutation that abolishes IGF-II binding. Mol Endocrinol 10, 642-651.
56. Pear WS, Nolan GP, Scott ML, &, Baltimore D, (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90, 8392-8396.
57. Schaffer BS, Lin M-F, Byrd JC, Park JHY, &, MacDonald RG, (2003) Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells. Endocrinology 144, 955-966.
58. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, &, Binoux M, (1986) Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 154, 138-143.
59. Hartman MA, Kreiling JL, Byrd JC, &, MacDonald RG, (2009) High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose 6-phosphate/insulin-like growth factor II receptor. FEBS J 27, 1915-1919.